EMA Authorised: Pheburane (sodium phenylbutyrate) — Eurocept International B. V.

View source ↗

Summary

The EMA authorised Pheburane (sodium phenylbutyrate) for treating carbamoyl-phosphate synthetase I deficiency, with decision on 17 December 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carbamoyl Phosphate Synthetase Deficiency

Drugs mentioned

• Pheburane (sodium phenylbutyrate)

Snippet

Status: Authorised. Therapeutic area: Carbamoyl-Phosphate Synthase I Deficiency Disease. MAH: Eurocept International B. V.. Decision date: 17/12/2024